References
- Clayton-Smith J, Donnai D. 1995. Fetal valproate syndrome. Journal of Medical Genetics 32:724–727.
- Dalens B, Raynaud EJ, Gaulme J. 1980. Teratogenicity of valproic acid. Journal of Pediatrics 97:332–333.
- DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. 1984. The fetal valproate syndrome. American Journal of Medical Genetics 19:473–481.
- Lindhout D, Omtzigt JG. 1992. Pregnancy and the risk of teratogenicity. Epilepsia 33:41–48.
- Kozma C. 2001. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. American Journal of Medical Genetics 98:168–175.
- Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery and Psychiatry 77:193–198.
- Ozkan H, Cetinkaya M, Köksal N, Yapici S. 2011. Severe fetal valproat syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. Journal of Maternal Fetal Neonatal Medicine 24:521–524.
- Usha K. 2006. Fetal valproate syndrome: a review. Paediatric and Perinatal Drug Therapy 7:123–130.
- Vajda FJ, O’brien TJ, Hitchcock A, Graham J, Cook M, Lander C, Eadie MJ. 2004. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience 11:854–858.